WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsPulse Biosciences Inc (PLSE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 33060364% more annual revenue ($28.43B vs $86,000). MDLN leads profitability with a 4.1% profit margin vs 0.0%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

PLSE

Avoid

16

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -4.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.03

$24.89 discount

UndervaluedFair: $66.92Overvalued

Intrinsic value data unavailable for PLSE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

PLSE1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

PLSE4 concerns · Avg: 3.8/10
Price/BookValuation
16.1x4/10

Trading at 16.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$958.23M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : PLSE

The strongest argument for PLSE centers on Debt/Equity.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : PLSE

The primary concerns for PLSE are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

MDLN is growing revenue faster at 14.8% — sustainability is the question.

PLSE generates stronger free cash flow (-15M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 16/100) and 14.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Pulse Biosciences Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Pulse Biosciences, Inc. is a bioelectrical medicine startup. The company is headquartered in Hayward, California.

Visit Website →

Want to dig deeper into these stocks?